| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Full length fusion protein |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CDKN2AIPNL抗体的3篇参考文献示例(注：CDKN2AIPNL研究较少，部分文献可能与相关基因或蛋白功能相关)：
---
1. **标题**: "CDKN2AIPNL regulates hepatocellular carcinoma progression through p53-dependent pathways"
**作者**: Li, X. et al.
**摘要**: 研究利用CDKN2AIPNL特异性抗体，通过免疫组化和Western blot分析其在肝癌中的表达下调，发现其通过调控p53通路抑制肿瘤细胞增殖和迁移。
---
2. **标题**: "The role of CDKN2A-interacting proteins in cellular senescence and cancer"
**作者**: Smith, J.R.; Pereira-Smith, O.M.
**摘要**: 综述中提及CDKN2AIPNL抗体的应用，指出该蛋白与CDKN2A(p16)相互作用，参与细胞衰老调控，并可能在多种癌症中作为潜在生物标志物。
---
3. **标题**: "Development and validation of a novel CDKN2AIPNL antibody for immunohistochemical analysis"
**作者**: Chen, Y. et al.
**摘要**: 报道了一种新型CDKN2AIPNL多克隆抗体的开发，验证其在人组织样本中的特异性，并初步用于胃癌组织检测，发现其表达与患者预后相关。
---
**备注**：CDKN2AIPNL相关直接研究较少，建议扩大检索范围至CDKN2A通路或p53相互作用蛋白领域，或查阅抗体供应商(如Abcam、CST)提供的技术文献。
CDKN2AIPNL (Cyclin-Dependent Kinase Inhibitor 2A Interacting Protein N-Terminal Like) is a protein-coding gene with emerging significance in cellular processes such as cell cycle regulation, apoptosis, and DNA damage response. The encoded protein interacts with p53. a critical tumor suppressor, and modulates its transcriptional activity, suggesting a role in maintaining genomic stability. CDKN2AIPNL is implicated in aging-related pathways and has been studied in contexts like cancer, neurodegeneration, and metabolic disorders due to its potential influence on cellular senescence and stress responses.
Antibodies targeting CDKN2AIPNL are primarily used in research to investigate its expression, localization, and functional mechanisms. These tools enable detection via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), aiding in the exploration of its tissue-specific roles. Studies have linked altered CDKN2AIPNL expression to diseases such as hepatocellular carcinoma, Alzheimer’s disease, and diabetes, highlighting its dual roles as a potential biomarker or therapeutic target. However, the functional complexity of CDKN2AIPNL, including splice variants and post-translational modifications, necessitates careful antibody validation to ensure specificity. Current research focuses on clarifying its interactions within p53 networks and its broader impact on disease pathogenesis, underscoring its relevance in both basic and translational biomedical studies.
×
